drugset
drugset / Trial / NCT01744665

A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation

NCT01744665 ↗

Phase 2 Completed 59 enrolled Novartis Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

To evaluate molecular relapse free rates 6 months after stopping nilotinib therapy in patients who achieve MR4.5

Timeline

Start
2013-08-12
Primary completion
2018-09-28
Completion
2018-09-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Nilotinib Small molecule 300 mg —

Indications

chronic myeloid leukemia